$28.71
0.74[2.65%]
At close: May 2
$28.71
0[0.00%]
After Hours: 4:03PM EDT
Morphic Holding
(NASDAQ:MORF)Latest News for Morphic Holding Stock (NASDAQ:MORF)
Morphic Holding Stock (NASDAQ: MORF)
Categories: All
Thursday, April 25, 2024
Friday, March 08, 2024
Thursday, February 22, 2024
Friday, December 08, 2023
Friday, November 03, 2023
Thursday, October 12, 2023
Thursday, September 28, 2023
Tuesday, September 26, 2023
Monday, September 25, 2023
- Gold Moves Lower; TransCode Therapeutics Shares SurgeLisa Levin - Sep 25, 2023, 2:43PM
- Morphic Therapeutic's Stock Plunges On Monday - Here's Why?Vandana Singh - Sep 25, 2023, 2:30PM
- Stifel Maintains Hold on Morphic Holding, Lowers Price Target to $33Benzinga Newsdesk - Sep 25, 2023, 2:26PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Sep 25, 2023, 1:31PM
- Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Sep 25, 2023, 1:04PM
- Nasdaq Turns Higher; SCYNEXIS Shares PlungeLisa Levin - Sep 25, 2023, 12:12PM
- Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023Benzinga Insights - Sep 25, 2023, 11:00AM
- Morphic shares are trading lower after BTIG downgraded the stock from Buy to Neutral.Benzinga Newsdesk - Sep 25, 2023, 9:11AM
- BTIG Downgrades Morphic Holding to NeutralBenzinga Newsdesk - Sep 25, 2023, 6:29AM
Friday, September 22, 2023
- Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day SessionLisa Levin - Sep 22, 2023, 2:22PM
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga Insights - Sep 22, 2023, 1:31PM
- Watching Morphic; Stifel Issues Note Titled 'UEG Abstract Endoscopic Improvement Rate Appears To Be Driving Weakness, Hard To Read Into Data Too Much Given Small Study'Benzinga Newsdesk - Sep 22, 2023, 11:56AM
- Watching Morphic; Traders Circulate 'MP009 Clinical Proof Of Principle And Favorable Tolerability Profile Shown With Orally Dosed MORF-057 As Induction Therapy For Moderately To Severely Active UC: Phase 2a Emerald-1 Study Results'; Shares Trading LowerBenzinga Newsdesk - Sep 22, 2023, 11:36AM
Wednesday, August 09, 2023
- Morphic Holding shares are trading lower after Stifel downgraded the stock from Buy to Hold and lowered its price target from $69 to $61.Benzinga Newsdesk - Aug 9, 2023, 11:54AM
- Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023Benzinga Insights - Aug 9, 2023, 11:00AM
- Stifel Downgrades Morphic Holding to Hold, Lowers Price Target to $61Benzinga Newsdesk - Aug 9, 2023, 5:05AM
Friday, August 04, 2023
Thursday, August 03, 2023
Friday, July 21, 2023
Friday, July 07, 2023
Thursday, June 15, 2023
Tuesday, June 06, 2023
Thursday, May 11, 2023
Wednesday, May 10, 2023
Friday, May 05, 2023
Wednesday, May 03, 2023
Tuesday, May 02, 2023
Wednesday, April 26, 2023
- 4 Analysts Have This to Say About Morphic HoldingBenzinga Insights - Apr 26, 2023, 11:00AM
- RBC Capital Maintains Outperform on Morphic Holding, Raises Price Target to $80Benzinga Newsdesk - Apr 26, 2023, 10:06AM
- BMO Capital Maintains Outperform on Morphic Holding, Raises Price Target to $106Benzinga Newsdesk - Apr 26, 2023, 8:30AM
Tuesday, April 25, 2023
- Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Apr 25, 2023, 1:33PM
- Morphic shares were trading lower after the company reported worse-than-expected Q1 EPS and sales results.Michael Horton - Apr 25, 2023, 12:14PM
- Wells Fargo Maintains Overweight on Morphic Holding, Raises Price Target to $80Benzinga Newsdesk - Apr 25, 2023, 12:09PM
- Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On TuesdayLisa Levin - Apr 25, 2023, 10:27AM
- Morphic Therapeutic's Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock SoarsVandana Singh - Apr 25, 2023, 9:54AM
- Morphic Holding shares were trading higher after the company announced that its open-label EMERALD-1 Phase 2a study of MORF-057 met its primary endpoint in adults with moderate to severe ulcerative colitis.Benzinga Newsdesk - Apr 25, 2023, 9:31AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Apr 25, 2023, 9:06AM
- Morphic Holding Q1 EPS $(0.90) Misses $(0.81) Estimate, Sales $521.00K Miss $2.14M Estimate; $421M In Cash, Cash Equivalents & Marketable Securities, Extending Runway Into 2H Of 2026Benzinga Newsdesk - Apr 25, 2023, 7:10AM
- Morphic Therapeutic's Open-Label EMERALD-1 Phase 2a Study of MORF-057 Met Primary Endpoint In Adults With Moderate To Severe Ulcerative Colitis; MORF-057 Was Generally Well Tolerated With No Safety Signal ObservedBenzinga Newsdesk - Apr 25, 2023, 7:07AM